Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Adenocarcinoma × catumaxomab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 5 Carcinoma, Ovarian Epithelial 4 Stomach Neoplasms 3 Peritoneal Neoplasms 3 Fallopian Tube Neoplasms 3 Carcinoma 3 Urinary Bladder Neoplasms 2 Neoplasms 2 Non-Muscle Invasive Bladder Neoplasms 1 Neoplasms, Glandular and Epithelial 1 Ascites 1 Adenocarcinoma 1

Interventions

Oxaliplatin 42 Gemcitabine 41 Fluorouracil 37 pembrolizumab 29 Capecitabine 29 Leucovorin 26 Docetaxel 25 Cisplatin 24 Paclitaxel 21 Carboplatin 18 Bevacizumab 17 Irinotecan 16 130-nm albumin-bound paclitaxel 16 Radiotherapy 15 Pemetrexed 15 Nivolumab 13 Albumin-Bound Paclitaxel 13 Cyclophosphamide 10 Ramucirumab 9 zolbetuximab 7 Trastuzumab 7 Radiosurgery 7 Drug Therapy 7 trastuzumab deruxtecan 6 cemiplimab 6 Taxes 6 Erlotinib Hydrochloride 6 Blood Specimen Collection 6 durvalumab 5 Sorafenib 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01504256 2018-01-23

CatuNeo

AIO-Studien-gGmbH

Phase 2 Completed

Adenocarcinoma, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡